ARCTURUS THERAPEUTICS HOLDINGS INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $2.74 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-03
- ARCTURUS THERAPEUTICS HOLDINGS INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00.
- ARCTURUS THERAPEUTICS HOLDINGS INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $0.00.
- ARCTURUS THERAPEUTICS HOLDINGS INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-06-30 was $0.00.
- ARCTURUS THERAPEUTICS HOLDINGS INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-03-31 was $2.74M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $2.74M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $30.19M, a 1551.59% increase from fiscal 2021.
- ARCTURUS THERAPEUTICS HOLDINGS INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $1.83M, a 34.41% increase from fiscal 2020.
- ARCTURUS THERAPEUTICS HOLDINGS INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $1.36M, a 76.82% decline from fiscal 2019.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $0.00 derived: sum of 3 quarters · filed 2026-03-03 | $2.74M 10-K · filed 2026-03-03 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $2.74M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $2.74M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $2.74M 10-Q · filed 2025-05-12 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $0.00 derived: sum of 2 quarters · filed 2025-03-06 | $30.19M 10-K · filed 2025-03-06 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $30.19M 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $30.19M 10-Q · filed 2023-08-07 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 derived: sum of 3 quarters · filed 2024-03-14 | $1.83M 10-K · filed 2024-03-14 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $1.83M 10-Q · filed 2022-11-09 | $2.51M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.83M 10-Q · filed 2022-08-09 | $2.51M derived: sum of 3 quarters · filed 2022-08-09 | $2.51M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $1.83M 10-Q · filed 2022-05-09 | $2.51M derived: sum of 2 quarters · filed 2022-05-09 | $2.51M derived: sum of 3 quarters · filed 2022-05-09 | $2.51M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $686.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $686.00K derived: sum of 2 quarters · filed 2022-03-01 | $686.00K derived: sum of 3 quarters · filed 2022-03-01 | $1.36M 10-K · filed 2022-03-01 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $674.00K 10-Q · filed 2021-11-09 | $674.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $674.00K 10-Q · filed 2021-08-10 | $674.00K derived: sum of 3 quarters · filed 2022-03-01 | $674.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $674.00K 10-Q · filed 2021-05-10 | $674.00K derived: sum of 2 quarters · filed 2022-03-01 | $674.00K derived: sum of 3 quarters · filed 2022-03-01 | $674.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $0.00 derived: sum of 3 quarters · filed 2022-03-01 | $5.87M 10-K · filed 2022-03-01 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | $5.87M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $5.87M 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $5.87M 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |